<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57173">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02109133</url>
  </required_header>
  <id_info>
    <org_study_id>4-2014-0058</org_study_id>
    <nct_id>NCT02109133</nct_id>
  </id_info>
  <brief_title>The Impacts of Surgical Visibility Through Deep Neuromuscular Blockade on Intraocular Pressure in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intraocular pressure is significantly increase during robot-assisted laparoscopic radical
      prostatectomy which is performed in a steep trendelenburg position at prolonged times of
      pneumoperitoneum. Therefore investigators decided to evaluate the impacts of surgical
      visibility through deep neuromuscular blockade on intraocular pressure in patients
      undergoing Robot-Assisted Laparoscopic Radical Prostatectomy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>compare the influence of surgical visibility through deep neuromuscular blockade on intraocular pressure in patients undergoing Robot-Assisted Laparoscopic Radical Prostatectomy.</measure>
    <time_frame>within 1hour after tracheal extubation</time_frame>
    <safety_issue>No</safety_issue>
    <description>T0: Pre-induction T1: 5min after anesthesia induction T2: 5 min after establish pneumoperitoneum T3: 30min after steep trendelenburg position T4: 60min after steep trendelenburg position T5: 5min after returning to horizontal position T6: 5min after tracheal extubation T7: 30min after tracheal extubation T8: 60min after tracheal extubation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Robot-Assisted Laparoscopic Radical Prostatectomy</condition>
  <arm_group>
    <arm_group_label>Deep neuromuscular blockade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deep neuromuscular blockade</description>
  </arm_group>
  <arm_group>
    <arm_group_label>moderate neuromuscular blockade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>moderate neuromuscular blockade</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>deep neuromuscular blockade</intervention_name>
    <description>deep neuromuscular blockade using rocuronium and reverse with sugammadex</description>
    <arm_group_label>Deep neuromuscular blockade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>moderate neuromuscular blockade</intervention_name>
    <description>moderate neuromuscular blockade using atracurium and reverse with neostigmine</description>
    <arm_group_label>moderate neuromuscular blockade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <arm_group_label>Deep neuromuscular blockade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <arm_group_label>Deep neuromuscular blockade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atracurium</intervention_name>
    <arm_group_label>moderate neuromuscular blockade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <arm_group_label>moderate neuromuscular blockade</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ASA class I-II

          2. obtaining written informed consent from the parents

          3. aged over 50 years who were undergoing robot- assisted laparoscopic prostatectomy

        Exclusion Criteria:

          1. eye surgery previously

          2. unstable angina or congestive heart failure

          3. concomitant eye disease (glaucoma, diabetic retinopathy, cataract, retinal
             detachment)

          4. high intraocular pressure over 30mmHg after screening test.

          5. uncontrolled hypertension (diastolic bp&gt;110mmHg)

          6. coagulopathy

          7. asthma

          8. hepatic failure

          9. renal failure(creatinine clearance &lt; 30 ml/min)

         10. drug hyperactivity

         11. neurological or psychiatric illnesses

         12. mental retardation

         13. patients who can`t read the consent form due to illiterate or foreigner

         14. previous malignant hyperthermia Hx

         15. drug medication which interact with muscle relaxant (anti-convulsant, certain
             antibiotics, magnesium etc)

         16. BMI &gt; 30kg/m2
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sun Jun Bai, MD</last_name>
    <phone>1-82-2-2228-2418</phone>
    <email>sjbai1@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sun Jun Bai, MD</last_name>
      <phone>1-82-2-2228-2418</phone>
      <email>sjbai1@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>March 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>deep neuromuscular blockade</keyword>
  <keyword>intraocular pressure</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atracurium</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
